Fatty Liver Disease (FLD) Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
Conditions: Nonalcoholic Fatty Liver Disease Interventions: Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part One; Drug: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two; Drug: Placebo - Study Part One; Drug: Placebo - Study Part Two Sponsors: ChemomAb Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Randomized Controlled Trial
Conditions: Type 2 Diabetes; Non Alcholic Fatty Liver Disease Intervention: Drug: Bempedoic acid Sponsors: Medanta, The Medicity, India; Diabetes & Endocrinology Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials

Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes
Conditions: Type 2 Diabetes; Non Alcholic Fatty Liver Disease Intervention: Drug: Bempedoic acid Sponsors: Medanta, The Medicity, India; Diabetes & Endocrinology Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials